Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GRACE K MOREHART

Allopathic & Osteopathic Physicians Family Medicine

NPI
1740219690
CMS profile
1238384
Location
BALDWIN PARK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$148.21

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $148.21 4

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $148.21 4

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GRACE K MOREHART

NPI 1740219690 · CMS profile ID 1238384

Allopathic & Osteopathic Physicians / Family Medicine

BALDWIN PARK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740219690?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GRACE K MOREHART, NPI 1740219690, CMS profile ID 1238384. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740219690?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). GRACE K MOREHART, NPI 1740219690, CMS profile ID 1238384. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740219690?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
GRACE K MOREHART, NPI 1740219690, CMS profile ID 1238384, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1740219690?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $148.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $122.7911/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184831699 CMS
E.R. Squibb & Sons, L.L.C. $9.8111/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184831667 CMS
E.R. Squibb & Sons, L.L.C. $6.2303/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184831567 CMS
E.R. Squibb & Sons, L.L.C. $9.3802/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184831545 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2025 $148.21 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $60,455.78 33
PY2024 Principal investigator $302,826.58 20
PY2023 Principal investigator $963,617.97 205
PY2022 Principal investigator $199,833.20 13
PY2021 Principal investigator $362,922.20 10
PY2020 Principal investigator $137,461.70 8
PY2019 Principal investigator $17,448.90 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

205 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $43,679.53 12/26/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1041412669
Principal investigator 1 Hoffmann-La Roche Limited $2,787.60 12/14/2023 Non-covered Recipient Entity
CITRIALS INC
TAAR1 4 for negative symptoms No dispute reported 06/30/2026 1040276919
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412683
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412697
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412711
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412725
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412741
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412757
Principal investigator 1 ModernaTX, Inc. $92,315.08 11/29/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1041412655
Principal investigator 1 Hoffmann-La Roche Limited $1,422.00 11/28/2023 Non-covered Recipient Entity
CITRIALS INC
TAAR1 4 for negative symptoms No dispute reported 06/30/2026 1040276905
Principal investigator 1 ModernaTX, Inc. $375.00 11/28/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042060549
Principal investigator 1 ModernaTX, Inc. $672.03 10/26/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412599
Principal investigator 1 Hoffmann-La Roche Limited $5,000.00 10/19/2023 Non-covered Recipient Entity
CITRIALS INC
TAAR1 4 for negative symptoms No dispute reported 06/30/2026 1040276893
Principal investigator 1 Hoffmann-La Roche Limited $11,605.00 10/04/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
Acute Schizophrenia study No dispute reported 06/30/2026 1040277813
Principal investigator 1 Hoffmann-La Roche Limited $1,000.00 10/02/2023 Non-covered Recipient Entity
CITRIALS INC
TAAR1 4 for negative symptoms No dispute reported 06/30/2026 1040276879
Principal investigator 1 ModernaTX, Inc. $672.03 10/02/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412583
Principal investigator 1 ModernaTX, Inc. $672.03 10/02/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412613
Principal investigator 1 ModernaTX, Inc. $672.03 10/02/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412627
Principal investigator 1 ModernaTX, Inc. $672.03 10/02/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412641
Principal investigator 1 ModernaTX, Inc. $672.03 09/11/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412483
Principal investigator 1 ModernaTX, Inc. $672.03 09/11/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412497
Principal investigator 1 ModernaTX, Inc. $672.03 09/11/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412511
Principal investigator 1 ModernaTX, Inc. $2,532.60 09/11/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412526
Principal investigator 1 ModernaTX, Inc. $2,532.60 09/11/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412541
Principal investigator 1 ModernaTX, Inc. $672.03 09/11/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412555
Principal investigator 1 ModernaTX, Inc. $280.87 09/11/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412569
Principal investigator 1 Hoffmann-La Roche Limited $408,680.00 08/18/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
Acute Schizophrenia study No dispute reported 06/30/2026 1040277731
Principal investigator 1 Hoffmann-La Roche Limited $41,701.25 08/18/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
Acute Schizophrenia study No dispute reported 06/30/2026 1040277763
Principal investigator 1 Hoffmann-La Roche Limited $4,500.00 07/25/2023 Non-covered Recipient Entity
CITRIALS INC
TAAR1 4 for negative symptoms No dispute reported 06/30/2026 1040276819
Principal investigator 1 Hoffmann-La Roche Limited $19,061.00 07/25/2023 Non-covered Recipient Entity
CITRIALS INC
TAAR1 4 for negative symptoms No dispute reported 06/30/2026 1040276833
Principal investigator 1 Hoffmann-La Roche Limited $6,000.00 06/27/2023 Non-covered Recipient Entity
CITRIALS INC
TAAR1 4 for negative symptoms No dispute reported 06/30/2026 1040276763
Principal investigator 1 Hoffmann-La Roche Limited $8,955.00 06/27/2023 Non-covered Recipient Entity
CITRIALS INC
TAAR1 4 for negative symptoms No dispute reported 06/30/2026 1040276779
Principal investigator 1 Hoffmann-La Roche Limited $1,000.00 06/22/2023 Non-covered Recipient Entity
CITRIALS INC
TAAR1 4 for negative symptoms No dispute reported 06/30/2026 1040276735
Principal investigator 1 ModernaTX, Inc. $1,063.19 05/24/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412425
Principal investigator 1 ModernaTX, Inc. $6,995.00 05/08/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042060047
Principal investigator 1 ModernaTX, Inc. $1,340.00 05/08/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042060243
Principal investigator 1 ModernaTX, Inc. $672.03 05/04/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412439
Principal investigator 1 ModernaTX, Inc. $672.03 05/04/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412453
Principal investigator 1 ModernaTX, Inc. $672.03 05/04/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412467
Principal investigator 1 ModernaTX, Inc. $672.03 04/27/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412337
Principal investigator 1 ModernaTX, Inc. $672.03 04/27/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412355
Principal investigator 1 ModernaTX, Inc. $672.03 04/27/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412369
Principal investigator 1 ModernaTX, Inc. $672.03 04/27/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412385
Principal investigator 1 ModernaTX, Inc. $672.03 04/27/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412399
Principal investigator 1 ModernaTX, Inc. $76.95 04/27/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412411
Principal investigator 1 ModernaTX, Inc. $66.40 04/24/2023 Non-covered Recipient Entity
CITRIALS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042309645
Principal investigator 1 ModernaTX, Inc. $1,250.00 03/17/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412153
Principal investigator 1 ModernaTX, Inc. $2,000.00 03/17/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412181
Principal investigator 1 ModernaTX, Inc. $2,000.00 03/17/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412253
Principal investigator 1 ModernaTX, Inc. $500.00 03/17/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412267
Principal investigator 1 ModernaTX, Inc. $8,000.00 03/17/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412281
Principal investigator 1 Hoffmann-La Roche Limited $16,951.50 03/14/2023 Non-covered Recipient Entity
CITRIALS INC
TAAR1 4 for negative symptoms No dispute reported 06/30/2026 1040276807
Principal investigator 1 ModernaTX, Inc. $672.03 03/08/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412125
Principal investigator 1 ModernaTX, Inc. $672.03 03/08/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412139
Principal investigator 1 ModernaTX, Inc. $672.03 03/08/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412167
Principal investigator 1 ModernaTX, Inc. $15.39 03/08/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412195
Principal investigator 1 ModernaTX, Inc. $672.03 03/08/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412209
Principal investigator 1 ModernaTX, Inc. $15.39 03/08/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412225
Principal investigator 1 ModernaTX, Inc. $672.03 03/08/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412239
Principal investigator 1 ModernaTX, Inc. $15.39 03/08/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412295
Principal investigator 1 ModernaTX, Inc. $672.03 03/08/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412310
Principal investigator 1 ModernaTX, Inc. $15.39 03/08/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412323
Principal investigator 1 Hoffmann-La Roche Limited $2,698.50 03/03/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
Acute Schizophrenia study No dispute reported 06/30/2026 1040278293
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $40,861.50 02/23/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 1014040409
Principal investigator 1 ModernaTX, Inc. $595.08 02/06/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412083
Principal investigator 1 ModernaTX, Inc. $595.08 02/06/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412097
Principal investigator 1 ModernaTX, Inc. $595.08 02/06/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041412111
Principal investigator 1 Hoffmann-La Roche Limited $18,288.00 01/27/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
Acute Schizophrenia study No dispute reported 06/30/2026 1040278165
Principal investigator 1 Hoffmann-La Roche Limited $58,750.00 01/27/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
Acute Schizophrenia study No dispute reported 06/30/2026 1040278183
Principal investigator 1 Hoffmann-La Roche Limited $33,482.70 01/27/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
Acute Schizophrenia study No dispute reported 06/30/2026 1040278199
Principal investigator 1 Hoffmann-La Roche Limited $5,403.60 01/18/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
Acute Schizophrenia study No dispute reported 06/30/2026 1040278145
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408437
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408451
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408465
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408481
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408495
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408507
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408523
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408537
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408551
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408566
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408581
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408593
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408609
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408625
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408639
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408655
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408667
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408681
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408697
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408711
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408725
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408739
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408753
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408767
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041408781
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041409889
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041409903
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041409917
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041409931
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041409947
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041409961
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041409975
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041409989
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410005
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410021
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410034
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410049
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410065
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410079
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410093
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410107
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410121
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410135
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410149
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410165
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410181
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410197
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410211
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410225
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410239
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410255
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410271
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410285
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410299
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410313
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410327
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410343
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410357
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410373
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410385
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410401
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410415
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410430
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410445
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410459
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410473
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410487
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410503
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410517
Principal investigator 1 ModernaTX, Inc. $2,405.97 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410531
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410545
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410559
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410579
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410593
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410607
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410621
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410635
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410649
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410665
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410679
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410693
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410707
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410721
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410737
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410749
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410763
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410777
Principal investigator 1 ModernaTX, Inc. $1,883.99 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410791
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410808
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410822
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410833
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410851
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410867
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410881
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410895
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410909
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410923
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410937
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410951
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410965
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410979
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041410993
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411007
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411023
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411039
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411055
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411069
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411083
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411097
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411111
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411127
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411143
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411157
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411171
Principal investigator 1 ModernaTX, Inc. $1,883.99 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411187
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411201
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411217
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411231
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411241
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411255
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411269
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411283
Principal investigator 1 ModernaTX, Inc. $1,063.19 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411299
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411314
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411329
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411343
Principal investigator 1 ModernaTX, Inc. $595.08 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411355
Principal investigator 1 ModernaTX, Inc. $2,405.97 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411371
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411379
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411393
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411407
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411421
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411435
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041411449